Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 9/20 | 0.63 |
| ▸ | PDCD1 | Q15116 | 7/20 | 0.59 |
| ▸ | CIB1 | Q99828 | 4/20 | 0.55 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.49 |
| ▸ | CTSG | P08311 | 1/20 | 0.47 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.45 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.45 |
| ▸ | LDLR | P01130 | 2/20 | 0.45 |
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19345169 | 0.99 | CD274 (0.62) | CD274PDCD1CIB1KLKB1CTSG | |
| SCHEMBL19345192 | 0.99 | CD274 (0.62) | CD274PDCD1CIB1KLKB1CTSG | |
| SCHEMBL19345630 | 0.98 | CD274 (0.61) | CD274PDCD1CIB1KLKB1CTSG | |
| SCHEMBL21548543 | 0.98 | CD274 (0.61) | CD274PDCD1CIB1KLKB1CTSG | |
| SCHEMBL19345180 | 0.98 | CD274 (0.61) | CD274PDCD1CIB1KLKB1CTSG | |
| SCHEMBL19345265 | 0.98 | CD274 (0.65) | CD274PDCD1CIB1KLKB1CTSG | |
| SCHEMBL19345200 | 0.98 | CD274 (0.61) | CD274PDCD1CIB1KLKB1CTSG | |
| SCHEMBL19754482 | 0.98 | CD274 (0.61) | CD274PDCD1CIB1KLKB1CTSG | |
| SCHEMBL19345641 | 0.98 | CD274 (0.62) | CD274PDCD1CIB1KLKB1CTSG | |
| SCHEMBL19754486 | 0.98 | CD274 (0.62) | CD274PDCD1CIB1KLKB1CTSG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3191113-B1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80 (B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL MYERS SQUIBB CO (US) | 2019-11-06 | — | — | EP | disclosed |